Solventum Corporation (SOLV) is a healthcare company in Minnesota with a market cap of $12.6 billion. They develop solutions for various healthcare needs using material and data science. SOLV will announce its Q2 earnings on August 7, with analysts expecting a profit of $1.45 per share.

Analysts predict SOLV will report a full-year EPS of $5.58, down 16.7% from the previous year. However, EPS is expected to rise 3.1% in fiscal 2026. The stock has outperformed the S&P 500, with a 31.4% increase over the past 52 weeks.

SOLV reported Q1 results on May 8, with shares up by 11.9% in the following two trading sessions. Their adjusted EPS of $1.34 exceeded Wall Street’s expectations, and revenue was $2.1 billion. The company expects full-year adjusted EPS between $5.45 to $5.65.

Analysts hold a “Moderate Buy” rating for SOLV stock, with an average price target of $85.50. Out of 12 analysts, four suggest a “Strong Buy,” seven recommend a “Hold,” and one advises a “Strong Sell.” The current price level indicates a potential 14.9% upside.

Read more at Yahoo Finance: What to Expect From Solventum’s Q2 2025 Earnings Report